Mepsevii

Chemical Namevestronidase alfa
Dosage FormInjection (intravenous; 10 mg/5 mL)
Drug ClassEnzymes
SystemNervous, Digestive, Musculoskeletal, Endocrine
CompanyUltragenyx Pharm Inc
Approval Year2017

Indication

  • To treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Mepsevii (vestronidase alfa) Prescribing Information2019Ultragenyx Pharmaceutical Inc.